PURPOSE: The aims of this analysis were to investigate the clinical features of extraskeletal osteosarcoma (ESOS) and examine the outcome after multi-modal therapy. METHODS: The co-operative osteosarcoma study-group database was searched for patients with extraskeletal osteosarcoma. Eligible patients were included in a retrospective analysis of patient, tumour and treatment related variables and outcome. As for conventional osteosarcoma, scheduled treatment included surgery and multi-agent chemotherapy. RESULTS: Seventeen eligible patients were identified with a median age of 44 years (range, 3-65 years). The thigh was the commonest tumour site. Two patients had a history of previous malignancies and two had primary metastases. Median follow-up was 3.2 years (range: 0.6-7.4 years) and at last follow-up, 11 patients were alive in complete remission, 3 patients were alive with disease and 3 patients had died of their disease. Three-year overall actuarial and event-free survival rates were 77% and 56%, respectively. Patients with macroscopically complete surgical remission had an improved overall survival (P = 0.0004). CONCLUSIONS: The patients in this retrospective study had a surprisingly good survival rate. This may be due to the combination of multi-agent chemotherapy with surgery, and we recommend this approach in the treatment of ESOS.
PURPOSE: The aims of this analysis were to investigate the clinical features of extraskeletal osteosarcoma (ESOS) and examine the outcome after multi-modal therapy. METHODS: The co-operative osteosarcoma study-group database was searched for patients with extraskeletal osteosarcoma. Eligible patients were included in a retrospective analysis of patient, tumour and treatment related variables and outcome. As for conventional osteosarcoma, scheduled treatment included surgery and multi-agent chemotherapy. RESULTS: Seventeen eligible patients were identified with a median age of 44 years (range, 3-65 years). The thigh was the commonest tumour site. Two patients had a history of previous malignancies and two had primary metastases. Median follow-up was 3.2 years (range: 0.6-7.4 years) and at last follow-up, 11 patients were alive in complete remission, 3 patients were alive with disease and 3 patients had died of their disease. Three-year overall actuarial and event-free survival rates were 77% and 56%, respectively. Patients with macroscopically complete surgical remission had an improved overall survival (P = 0.0004). CONCLUSIONS: The patients in this retrospective study had a surprisingly good survival rate. This may be due to the combination of multi-agent chemotherapy with surgery, and we recommend this approach in the treatment of ESOS.
Authors: S Bielack; B Kempf-Bielack; D Schwenzer; T Birkfellner; G Delling; V Ewerbeck; G U Exner; N Fuchs; U Göbel; N Graf; U Heise; K Helmke; A R von Hochstetter; H Jürgens; R Maas; N Münchow; M Salzer-Kuntschik; J Treuner; U Veltmann; M Werner; W Winkelmann; A Zoubek; R Kotz Journal: Klin Padiatr Date: 1999 Jul-Aug Impact factor: 1.349
Authors: N Fuchs; S S Bielack; D Epler; P Bieling; G Delling; D Körholz; N Graf; U Heise; H Jürgens; R Kotz; M Salzer-Kuntschik; P Weinel; M Werner; K Winkler Journal: Ann Oncol Date: 1998-08 Impact factor: 32.976
Authors: Karen Wodowski; D Ashley Hill; Alberto S Pappo; Stephen J Shochat; Larry E Kun; Sheri L Spunt Journal: J Pediatr Hematol Oncol Date: 2003-01 Impact factor: 1.289
Authors: Jonas Paludo; Karen Fritchie; Candace L Haddox; Peter S Rose; Carola A S Arndt; Randolph S Marks; Evanthia Galanis; Scott H Okuno; Steven I Robinson Journal: Am J Clin Oncol Date: 2018-09 Impact factor: 2.339